The intestinal ulcerogenic activity of the weak prostaglandin synthesis inhibitor drug Wy-4 1,770 [5Hdibenzo(a,d)-cyclohepten-5-ylidine] was contrasted with the potent synthesis inhibitor, indomethacin, in rats to establish the relationship of inhibition of prostaglandin synthesis to the intestinal damage. Wy-4 1,770 induced superficial erosions only in the cecum 26 hr after a single oral dose of 250 or 500 mg/kg of the drug, progressing to ulcers after 5 days dosing with ultrastructural evidence of bacteria in the mucosa. Indomethacin (5 or 10 rng/kg PO) induced mucosal erosions in the ileum, initially at 26 hr progressing to ulcers after 5 days. Fewer bacteria were seen in the ileal mucosa of indomethacin-treated rats. Both drugs reduced prostaglandin E in those regions of the intestine coincident with the known accumulation of these drugs at sites of mucosal injury. Site-specific intestinal damage from these 2 drugs is associated with inhibition of the synthesis of mucosal-protective prostanoids, followed by pronounced bacterial invasion through the damaged mucosae with consequent appearance of local immuno-inflammatory reactions.
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frequently than previously appreciated because of difficulties in detecting such damage in deeper regions of the GI tract, less accessible to investigative procedures, e.g., endoscopy (see review, ref. 20) .
Studies in laboratory animals have shown that most ofthose NSAI drugs known to cause ulceration of the intestinal mucosa in rats (e.g., diclofenac, the fenamates, indomethacin, and phenylbutazone) also exhibit enterohepatic circulation of these drugs (9, 19, 20) . Thus, it appears that persistent re-exposure ofthe intestinal mucosa to the recycled drug appears to be a major factor responsible for the predisposition of the intestinal tract of laboratory animals towards injury by these NSAI drugs (9, 20) .
An anti-inflammatory drug developed recently, Wy-4 1,770 [(5H-dibenzo(a,d)cyclohepten-5-ylidene) acetic acid], was found to be a very weak prostaglandin synthesis inhibitor and coincidently exhibited virtually no detectable gastric imtancy in rats (4) . However, during preliminary toxicological screening it was found that prolonged oral administration of high doses (225-300 mg/kg/d) of Wy-41,770 produced ileo-cecal lesions in rats, but not in dogs (1 4) or mice (Rainsford, unpublished stud-ies) . It was of interest to explore the nature of this lesion since 1) lower GI ulcerogenicity in rats is generally produced by potent PG synthesis inhibitors (13, 20, 24, 25) , 2) the pathogenesis of indomethacin-induced intestinal ulceration is considered to involve drug-induced inhibition of the mucosal biosynthesis of cytoprotective prostaglandins (24) yet dkspite this Wy-4 1,770 is a very weak prostaglandin synthesis inhibitor (4) , and 3) the main site ofmucosal ulcers and erosions induced by NSAI drugs is predominantly in the jejuno-ileal region (20) with little, if any, damage being evident in the cecal region such as seen in the long-term toxicological screening with Wy-4 1,770. To define further the extent and severity of the intestinal lesion, which is obviously of considerable clinical importance, and also to determine the factors responsible for its development, studies were performed to: 1) Establish the time-sequence and dose-response effects of orally administered Wy-41,770 compared with that of the known intestinal ulcerogen, indomethacin, in rats. 2) Determine if the presence of intestinal flora is important in the genesis of cecal ulcers induced by oral Wy-41,770 as previously shown for indomethacin (13, 25). 3) Examine the sequelae of surface mucosal and finestructural changes by scanning and transmission electron microscopy in the intestinal tract of rats given Wy-4 1,770 and indomethacin, and correlate structural changes with these drugs with alterations in prostaglandin E content therein, so as to gain insight into the cellular actions of these drugs relevant to their intestinal ulcerogenicity. A preliminary report of this work was presented at the 8th meeting of the European Workshop on Inflammation in London (2 1).
MIXHODS
The studies were performed in adult male and female Sprague-Dawley rats obtained from Tuck & Sons, Rayleigh, Essex, UK.
The drugs were all dosed orally as 1 -ml vigorously mixed fine suspensions (prepared by homogenizing in distilled water immediately before use) to groups of 5-10 animals as follows: These animals were killed 20 hr after the final dose, i.e., on the fifth day.
All animals were killed by stunning and cervical fracture and a full macroscopic and binocular microscopic visual examination of the entire gastrointestinal tract was performed. The numbers of mucosal lesions and their severity were recorded as previously described (1 8) .
Light Microscopy
Selected areas of the intestinal tract wherein lesions were visible were fixed in 4% formaldehyde in saline, embedded in paraffin, and sections stained with hematoxylin and eosin, or periodic acid Schiffs reagent (PAS) for light microscopy. Also, sections from apparently undamaged areas of the cecum of indomethacin-treated rats and the jejunum and ileum from rats given Wy-4 1,770 were prepared and examined by light microscopy to confirm the negative appearance of mucosal damage in these, regions (see Results).
Scanning Electron Microscopy (SEM)
Sections of ileal and cecal mucosa from rats given 500 mg/kg Wy-41,770 PO, 10 mg/kg indomethacin PO, or 1 ml H 2 0 for 4, 7, and 26 hr were fixed in 3% glutaraldehyde in 0.1 M sodium phosphate buffer pH 7.4 for 1-5 days before critical point drying, mounting, and sputter-coating with gold. Specimens were examined by a JEOL JEM lOOC scanning electron microscope at an accelerating voltage of 100 kV.
Transmission Electron Microscopy (TEM)
Tissues were selected for TEM from rats dosed as for the SEM studies, as well as those from an additional group of animals dosed with 50 mgkg Wy-41,770 for 5 days. These tissues were fixed (within 30 sec following death) in 2.5% glutaraldehyde and 2% formaldehyde prepared in 0.1 M sodium phosphate buffer pH 7.4 for 1-6 hr, post-fixed in 1% osmium tetroxide in 0.1 M sodium phosphate buffer pH 7.4. Some tissues were fixed by lumenal perfusion with 10-20 ml of the glutaraldehyde/ formaldehyde fixative and thereafter sections fixed as described in this fixative for 1-6 hr. The sections were subsequently dehydrated through a graded series of aqueous ethanol solutions and 1,Zepoxypropane prior to embedding in Epon. Thin sections were selected following examination of toluidine blue thick sections, and the former stained with lead citrate (23) and uranyl acetate (30) prior to exami- nation under a Philips 300 EM at an accelerating voltage of 100 kV.
Assays of Prostaglandiir E Coiiterit
Since it was found that the sites of mucosal damage were, for indomethacin in the ileum, and for Wy-41,770 in the cecum, it was decided to obtain sections of a) the ileal mucosa from rats dosed orally with 10 mg/kg indomethacin for 3,6, and 26 hr and, b) the cecum and ileum from rats given Wy-41,770 500 mg/kg PO for 26 hr, respectively, for the assay of prostaglandin E (PGE) content. These times were selected because in addition to being most likely for lesion formation, it is also known as the approximate time'for peak levels ofthese drugs to be present in those regions of the intestine which were selected (9, 12, 22, 26) .
Sections of the mucosae were rapidly frozen on dry ice and approximately 0.2 g of the superficial ,mucosa scraped off from the serosa by chilled scalpel for homogenizing in 5 ml 0.2 M citric acid, pH 3, followed by 2 ml ethanol (both kept' at 4°C). The samples were subsequently centrifuged (3,000 x g for 10 min at 4°C) and the prostaglandins present in the supernatant were then obtained by purification on Sep Pak@ C18 reverse phase minicolumns (Waters Associates, Milford, MA, USA) as previously described (22). The PGE content in the dried methyl formate fractions thus obtained was determined by Travenol radioimmunoassay kit (Travenol-Genentech Diagnostics, Cambridge, MA, USA) according to the manufacturer's instructions. The protein content in the acidified ethanol precipitate from the above extraction was determined by the Lowry method (1 5 ) following digestion of the precipitate in 1 M NaOH for 24 hr.
RESULTS

Gross Pathology
Large ulcers present in the cecum together with small erosions in the ileal-cecal valve were observed in all rats given repeated oral doses of 250 and 500 mg/kg/d Wy-4 1,770 PO for 4 days (Table I) . Small erosions were present in the cecum of 25% of rats given 100 mg/kg/d PO Wy-41,770 but no mucosal erosions were observed in the ileum of these animals. No mucosal erosions were visible in the intestine nor for that matter any other region of the GI tract in those animals dosed with the lower dose of 50 mg/kg/d Wy-4 1,770 after 5 days.
In comparison, all the rats repeatedly dosed with indomethacin (5 mg/kg/d) developed ulcers in the ileum and jejunum after 5 days. In some cases even peritonitis and adhesions were evident. No lesions were observed in the cecum. No gastro-intestinal damage was evident in control animals for this group.
In rats dosed with the antibiotic neomycin (50 mg/kg PO) together with 250 or 500 mg/kg/d Wy-41,770 for 4 days, a marked reduction in the severity and numbers of mucosal erosions was observed compared with that in animals receiving Wy-41,770 alone (Table I) .
The first visible signs of damage in the intestinal tract of rats given Wy-4 1,770 was evident at 26 hr. Here approximately 60% of the rats showed the presence of small hemorrhagic lesions in the cecal mucosa after a single dose of 500 mg/kg Wy- 4 1,770 with no other damage in the gastro-intestinal tract being visible. No damage was evident in the gastrointestinal tract of control animals. In contrast, indomethacin (5 or 10 mg/kg) given for 26 hr or 4 days induced mucosal damage visible to the unaided eye, principally in the jejuno-ileal region, in agreement with previous observation (13, 25) . At 26 hr, 80% of the rats given a single dose of 10 mg/kg indomethacin PO had hemorrhagic lesions in the ileum, whereas by 4 days, 100% of the rats had erosions, ulcers, and adhesions of the intestinal tract to the abdominal wall.
Scanning Electron Microscopy
The initial appearance of damage to the cecum at 26 hr after oral administration of 500 mg/kg Wy-4 1,770 comprised of isolated cellular desquamation and injury (Fig. la) , and mucous cell swelling ( Fig.  1 b) . Indomethacin also induced focal erosions (Fig.  2) as well as the bleb-like swelling to mucous cells and isolated cellular injury as seen with Wy-4 1,770. While no evidence of superficial mucosal cell injury was evident 4 and 7 hr following oral administration of these drugs, there was some mucosal swelling and adhesion of considerable numbers of long-thin bacterial rods to the surface mucosa.
Light and Transmission Electron
Microscopic Observations
The most significant pathological changes in the cecal mucosa of animals given Wy-4 1,770 were evident 26 hr after single and 5 days after repeated doses of 500 mg/kg Wy-4 1,770 ( Fig. 3a, b) . When visualized by transmission electron microscopy (TEM) at 26 hr, extensive cell lysis and swelling (Fig.  3b ) and areas of sloughing are apparent. Also, considerable numbers of bacterial rods and accompanying leukocyte infiltration were evident in both the areas where lesions occurred as well as in the apparently undamaged mucosal tissue (i.e., when observed by light microscopy) adjacent to these regions ( Fig. -3a) .
Light microscopic observations of the cecal ulcers which had developed 5 days after oral administration of 500 mg/kg/d Wy-4 1,770 showed extensive numbers of dead cells in the focus of the ulcer and large numbers of leukocytes immediately &low this area of dead cells. Extensive leukocyte invasion was also seen by TEM especially in the interstitial region of the mucosa and was accompanied by apparent collagen dissolution and interstitial edema. Considerable numbers of bacterial rods were also evident in this otherwise undamaged tissue (Le., when viewed by light microscopy) adjacent to the cecal ulcers in those animals given 500 mg/kg/d of Wy-4 1,770 for 5 days.
Only sporadic reduction in the length of microvilli, vacuole formation (especially in the endothelial cells of microcapillaries) and accompanying edema was present in the ileal region of those animals given repeated doses of 500 mg/kg/d of this drug.
Occasionally, mucous cell damage was observed, otherwise the lesions were essentially very small and superficial with no penetration into the regions of the mucosa.
Despite careful searching, there was no macro-or microscopic evidence of mucosal damage in the cecal or ileal regions of rats given the low doses of 50 mg/kg Wy-41,770 for 4 days. In rats given indomethacin (10 mg/kg) for 26 hr, there was extensive damage to the surface epithelial cells of the ileum. This was evident initially at 4 hr and most pronounced at 26 hr. At this stage, inflammatory cells were abundant in lesioned areas ( Fig. 4 ) especially in areas adjacent to Payer's patches. Some signs of extravasated blood cells in interstitial areas were evident. Numerous small transparent vesicles were also present in the cytoplasm of endothelial cells.
After 4 days of repeated oral dosage of indomethacin (5 mg/kg/d), the cells adjacent to focal lesions appeared relatively undifferentiated in having few endoplasmic reticular structures or ribosomes but with more abundant mitochondria. Some evidence of bacterial invasion was apparent in the ileal mucosa (damaged or undamaged) of indomethacin-treated rats but not as pronounced as observed with Wy-4 1,770.
Efects on Prostaglandin Production
The results in Fig. 5 show that Wy-41,770 caused a reduction in mucosal PGE in the cecum but not the ileum 26 hr after oral administration. This effect in reducing PGE in the cecum corresponds to the known pattern of drug accumulation of this drug in this region of the GI tract with appreciably less of the drug being present in the ileum after oral administration (26) .
In comparison, indomethacin 10 mg/kg po caused a reduction of 85.1% in the mucosal content of PGE in the ileum at 3 hr (control = 393 k 250 ng/g protein, cf. indomethacin = 58.5 f 42.5 ng/g; n = 5 per group; p < 0.05, Student's t-test). However, treatment with the drug for 6 or 26 hr did not produce any statistically significant reduction in the content of PGE. This effect corresponds to the pattern of drug uptake into mucosal cells inasmuch as peak levels of indomethacin in the rat intestinal mucosa occur at 3 hr and progressively decline thereafter (22) .
DISCUSSION
The SEM and TEM observations show that the pathological reactions in the cecum are evident 26 hr following the first oral dose of 500 mg/kg Wy-41,770 ( Figs. 1 and 3a, b) . It is clear that there is extensive surface mucosal cell damage accompanied sharp demarcation between eroded cells and normal mucosa. Similar but fewer erosions were seen in the cecal mucosa of rats given 500 mg/kg Wy-41,770 for 26 hr. by massive bacterial invasion in the mucosa tissue in rats given this high dose of Wy-41,770 (Fig. 3a,  b ). Concurrent treatment with neomycin was found to markedly reduce the number and area of cecal erosions and ulcers induced by repeated 4 days of dosing of 250 and 500 mg/kg/d Wy-41,770 (Table  I) . These results strongly suggest a bacterial involvement in the drug-induced intestinal pathology. Indomethacin-induced intestinal damage in the rat is known to be initiated by bacterial 8-glucuronidases hydrolyzing indomethacin-glucuronide secreted from the bile into the intestine so repeatedly exposing the intestinal mucosa to imtant actions of unconjugated indomethacin (9, 13) . Thus, since an identical bacterial-derived mechanism causes release of Wy-4 1,770 from its glucuronide conjugate which then accumulates in the cecum of rats (12, 26) , this could lead to drug-induced breakdown in the mucosal bamer in the cecum so facilitating invasion of bacteria into the cecal mucosa as well as reduced synthesis of mucosal protective prostaglandin E (Fig. 5) . Presumably, a localized immunological reaction is established following the bacterial invasion which accounts for the massive accumulation of leukocytes, whereupon cell-mediated tissue destruction ensures, possibly as a consequence of phagocyte-induced autolytic reactions.
It was found that the cecal and to a much lesser extent damage in the ileal-cecal valve induced by Wy-41,770 is only manifest at high doses (100 to 500 mg/kg) of the drug, which are in excess of those required for the therapeutic actions of the drug in adjuvant arthritic rats (EDSo = 16 mg/kg) (4) . At repeated doses of 50 mg/kg, it is clear that even when observed by TEM, the mucosa of the cecum and ileum there are no signs of pathology (see Results).
The predominance of pathological reactions in the cecum by Wy-41,770 is in marked contrast to that by indomethacin which induced damage in the ileum and jejunem in rats. These differences correlate with the known pattern of drug accumulation in the ileum with indomethacin (9) or cecum in the case of Wy-4 1,770 (12, 26) , respectively.
The possibility that inhibition of the mucosal biosynthesis of cytoprotective prostaglandins (PGs) is a factor in the pathogenesis of damage in these sites of the intestinal tract is shown by the results in Fig.  5 . Thus, lesions developed only in those sites wherein reduction of PGE occurred. While Wy-4 1,770 is a weak PG synthesis inhibitor (4), it appears that appreciable concentrations of the conjugated drug can accumulate in the cecum following hydrolysis (1 2,26) following administration of these high doses of the drug, sufficient to significantly inhibit PG synthesis.
The principal microscopic changes observed during the development of indomethacin-induced ileal damage are a) changes to the mucosal microvilli at 4 and 7 hr followed by surface epithelial cells at 26 hr ( Fig. 2 ; see Results) accompanied by b) appearance of inflammatory cells in the focus of a lesion ( Fig. 4 ) especially in the mucosa adjacent to Payer's nodules. The possibility of indomethacin-induced intestinal lesions occurring in the mucosa near Pay-. mucosal damage. These formulations have theeffect ofshifting the main site of absorption into the lower regions of the intestinal tract. This raises the possibility that the accompanying mucosal damage which could occur with the predominant absorption in this region could facilitate invasion of bacterial and food antigens so facilitating the observed cellular-immune response. Presumably, the relatively sterile environment created by the acidic pH conditions in the stomach reduces the possibility of such profound cellular-immune reactions occurring in this region of the GI tract.
The cellular involvement in the pathogenesis Wy-4 1,770-induced cecal ulceration has some resemblance, in part, to that seen in the earlier stages of inflammatory bowel diseases (IBDs) in man (7) . Thus, Wy-4 1,770-induced cecal damage in rats may be a useful animal model to screen for drugs to treat these conditions. This aspect is currently being investigated further.
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